Corrigendum to: Nitric Oxide Controls Fat Deposition in Dystrophic Skeletal Muscle by Regulating Fibro-Adipogenic Precursor Differentiation: NO and Fibro-Adipogenic Precursor Differentiation (STEM CELLS, (2014), 32, 4, (874-885), 10.1002/stem.1587);Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation

Stem Cells

Volumn 32, Issue 4, 2014, Pages 874-885

  Cordani, Nicoletta ^a   Pisa, Viviana ^b   Pozzi, Laura ^a   Sciorati, Clara ^c   Clementi, Emilio ^a,b  

^a SCIENTIFIC INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Adipocytes; Fibro adipogenic precursors; Fibrosis; MicroRNA; Nitric oxide; Skeletal muscle dystrophy

Indexed keywords

CYCLIC GMP; MICRORNA; MICRORNA 27B; MOLSIDOMINE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; MIRN27 MICRORNA, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; IN VITRO STUDY; LIPID STORAGE; MOLECULAR BIOLOGY; MOUSE; MYOFIBROSIS; NONHUMAN; PROTEIN EXPRESSION; SKELETAL MUSCLE; TISSUE REGENERATION; ANIMAL; GENETICS; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CYCLIC GMP; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MICRORNAS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NITRIC OXIDE; PPAR GAMMA;

EID: 84896361698     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2816     Document Type: Erratum

References (66)

1. Emery AE,. The muscular dystrophies. Lancet 2002; 359: 687-695.
2. Filippin LI, Moreira AJ, Marroni NP, et al. Nitric oxide and repair of skeletal muscle injury. Nitric Oxide 2009; 21: 157-163.
3. Kaminski HJ, Andrade FH,. Nitric oxide: Biologic effects on muscle and role in muscle diseases. Neuromuscul Disord 2001; 11: 517-524.
4. Nisoli E, Carruba MO,. Nitric oxide and mitochondrial biogenesis. J Cell Sci 2006; 119: 2855-2862.
5. Stamler JS, Meissner G,. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001; 81: 209-237.
6. Brenman JE, Chao DS, Xia H, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 1995; 82: 743-752.
7. Chao DS, Hwang PM, Huang F, et al. Localization of neuronal nitric oxide synthase. Methods Enzymol 1996; 268: 488-496.
8. Crosbie RH, Barresi R, Campbell KP,. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002; 16: 1786-1791.
9. Torelli S, Brown SC, Jimenez-Mallebrera C, et al. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004; 30: 540-545.
10. Gucuyener K, Ergenekon E, Erbas D, et al. The serum nitric oxide levels in patients with Duchenne muscular dystrophy. Brain Dev 2000; 22: 181-183.
11. Tidball JG, Wehling-Henricks M,. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Mol Genet Metab 2004; 82: 312-320.
12. Wehling M, Spencer MJ, Tidball JG,. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001; 155: 123-131.
13. Filippin LI, Cuevas MJ, Lima E, et al. Nitric oxide regulates the repair of injured skeletal muscle. Nitric Oxide 2009; 24: 43-49.
14. Voisin V, Sebrie C, Matecki S, et al. L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 2005; 20: 123-130.
15. Percival JM, Whitehead NP, Adams ME, et al. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012; 228: 77-87.
16. Sciorati C, Staszewsky L, Zambelli V, et al. Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacol Res 2013; 73: 35-43.
17. Brunelli S, Sciorati C, D'Antona G, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007; 104: 264-269.
18. Sciorati C, Buono R, Azzoni E, et al. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol 2010; 160: 1550-1560.
19. Sciorati C, Miglietta D, Buono R, et al. A dual acting compound releasing nitric oxide (NO) and ibuprofen, Ncx 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res 2011; 64: 210-217.
20. D'Angelo MG, Gandossini S, Martinelli Boneschi F, et al. Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res 2012; 65: 472-479.
21. Drenning JA, Lira VA, Simmons CG, et al. Nitric oxide facilitates NFAT-dependent transcription in mouse myotubes. Am J Physiol Cell Physiol 2008; 294: C1088-1095.
22. Betters JL, Lira VA, Soltow QA, et al. Supplemental nitric oxide augments satellite cell activity on cultured myofibers from aged mice. Exp Gerontol 2008; 43: 1094-1101.
23. Anderson JE,. A role for nitric oxide in muscle repair: Nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell 2000; 11: 1859-1874.
24. Anderson J, Pilipowicz O,. Activation of muscle satellite cells in single-fiber cultures. Nitric Oxide 2002; 7: 36-41.
25. Tatsumi R, Liu X, Pulido A, et al. Satellite cell activation in stretched skeletal muscle and the role of nitric oxide and hepatocyte growth factor. Am J Physiol Cell Physiol 2006; 290: C1487-1494.
26. De Palma C, Falcone S, Pisoni S, et al. Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiation. Cell Death Differ 2010; 17: 1684-1696.
27. Buono R, Vantaggiato C, Pisa V, et al. Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells 2011; 30: 197-209.
28. Joe AW, Yi L, Natarajan A, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol 2010; 12: 153-163.
29. Uezumi A, Fukada S, Yamamoto N, et al. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat Cell Biol 2010; 12: 143-152.
30. Uezumi A, Ito T, Morikawa D, et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci 2011; 124: 3654-3664.
31. Pretheeban T, Lemos DR, Paylor B, et al. Role of stem/progenitor cells in reparative disorders. Fibrogenesis Tissue Repair 2012; 5: 20.
32. Paylor B, Natarajan A, Zhang RH, et al. Nonmyogenic cells in skeletal muscle regeneration. Curr Top Dev Biol 2011; 96: 139-165.
33. Rodeheffer MS,. Tipping the scale: Muscle versus fat. Nat Cell Biol 2010; 12: 102-104.
34. Castoldi G, Di Gioia CR, Bombardi C, et al. MiR-133a regulates collagen 1A1: Potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 2011; 227: 850-856.
35. Jennewein C, von Knethen A, Schmid T, et al. MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization. J Biol Chem 2010; 285: 11846-11853.
36. Karbiener M, Fischer C, Nowitsch S, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 2009; 390: 247-251.
37. Lin Q, Gao Z, Alarcon RM, et al. A role of miR-27 in the regulation of adipogenesis. FEBS J 2009; 276: 2348-2358.
38. Messin R, Opolski G, Fenyvesi T, et al. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris. Int J Cardiol 2005; 98: 79-89.
39. Fukada S, Higuchi S, Segawa M, et al. Purification and cell-surface marker characterization of quiescent satellite cells from murine skeletal muscle by a novel monoclonal antibody. Exp Cell Res 2004; 296: 245-255.
40. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
41. Greenberg AS, Egan JJ, Wek SA, et al. Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J Biol Chem 1991; 266: 11341-11346.
42. Siersbaek R, Nielsen R, Mandrup S,. Transcriptional networks and chromatin remodeling controlling adipogenesis. Trends Endocrinol Metab 2011; 23: 56-64.
43. Blau HM, Webster C, Pavlath GK,. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 1983; 80: 4856-4860.
44. Relaix F, Zammit PS,. Satellite cells are essential for skeletal muscle regeneration: The cell on the edge returns centre stage. Development 2012; 139: 2845-2856.
45. Morgan JE, Zammit PS,. Direct effects of the pathogenic mutation on satellite cell function in muscular dystrophy. Exp Cell Res 2010; 316: 3100-3108.
46. Natarajan A, Lemos DR, Rossi FM,. Fibro/adipogenic progenitors: A double-edged sword in skeletal muscle regeneration. Cell Cycle 2010; 9: 2045-2046.
47. Heredia JE, Mukundan L, Chen FM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 2013; 153: 376-388.
48. Mozzetta C, Consalvi S, Saccone V, et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med 2013; 5: 626-639.
49. Cornelius P, MacDougald OA, Lane MD,. Regulation of adipocyte development. Annu Rev Nutr 1994; 14: 99-129.
50. Tontonoz P, Hu E, Spiegelman BM,. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 1995; 5: 571-576.
51. Tontonoz P, Hu E, Spiegelman BM,. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
52. Zhang J, Fu M, Cui T, et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 2004; 101: 10703-10708.
53. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-233.
54. Greco S, De Simone M, Colussi C, et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 2009; 23: 3335-3346.
55. Cacchiarelli D, Legnini I, Martone J, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011; 3: 258-265.
56. Cacchiarelli D, Martone J, Girardi E, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 2010; 12: 341-351.
57. Deng Z, Chen JF, Wang DZ,. Transgenic overexpression of miR-133a in skeletal muscle. BMC Musculoskelet Disord 2011; 12: 115.
58. Zhu H, Bhattacharyya BJ, Lin H, et al. Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals. J Neurosci 2013; 33: 7308-7324.
59. Cazzella V, Martone J, Pinnaro C, et al. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther 2012; 20: 2134-2142.
60. Colussi C, Mozzetta C, Gurtner A, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 2008; 105: 19183-19187.
61. Tengan CH, Rodrigues GS, Godinho RO,. Nitric oxide in skeletal muscle: Role on mitochondrial biogenesis and function. Int J Mol Sci 2012; 13: 17160-17184.
62. Nisoli E, Falcone S, Tonello C, et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci USA 2004; 101: 16507-16512.
63. De Palma C, Clementi E,. Nitric oxide in myogenesis and therapeutic muscle repair. Mol Neurobiol 2012; 46: 682-692.
64. Serrano AL, Munoz-Canoves P,. Regulation and dysregulation of fibrosis in skeletal muscle. Exp Cell Res 2010; 316: 3050-3058.
65. Serrano AL, Mann CJ, Vidal B, et al. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol 2011; 96: 167-201.
66. Zordan P, Sciorati C, Campana L, et al. The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. Eur J Pharmacol 2013; 715: 296-303.